
Denali Therapeutics DNLI
€ 18.18
3.89%
Quartalsbericht 2025-Q3
hinzugefügt 06.11.2025
Denali Therapeutics Kurshistorie 2011-2026 | DNLI
Kurshistorie Jährlich Denali Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.5 | 18.5 | 26.8 | 32.6 | 71.8 | 19.8 | 21.8 | 22.9 | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 71.8 | 18.5 | 29.1 |
Kurshistorie anderer Aktien in der Pharmaeinzelhändler
| Name | Kurshistorie | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
18.2 | - | 2.43 % | $ 254 M | ||
|
AbCellera Biologics
ABCL
|
3.22 | $ 3.46 | 1.72 % | $ 1.03 B | ||
|
Altimmune
ALT
|
3.61 | $ 3.47 | 3.89 % | $ 306 M | ||
|
Amgen
AMGN
|
369 | $ 350.07 | 0.63 % | $ 188 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
26.7 | $ 19.49 | -0.05 % | $ 911 M | ||
|
I-Mab
IMAB
|
0.68 | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
3.36 | - | 2.54 % | $ 160 B | ||
|
Ascendis Pharma A/S
ASND
|
216 | $ 220.18 | -0.77 % | $ 5 B | ||
|
Biophytis SA
BPTS
|
0.33 | - | -13.47 % | $ 169 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
13.8 | $ 14.83 | 5.78 % | $ 1.99 B | ||
|
Midatech Pharma plc
MTP
|
0.29 | - | -18.52 % | $ 27.3 M | ||
|
Autolus Therapeutics plc
AUTL
|
1.66 | $ 1.42 | 3.64 % | $ 362 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.3 | - | - | $ 26.5 M | ||
|
Axsome Therapeutics
AXSM
|
174 | $ 154.69 | -1.42 % | $ 7.7 B | ||
|
ARCA biopharma
ABIO
|
28.8 | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
5.72 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
13 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
13.5 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
28.5 | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
2.13 | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
3.37 | - | 4.01 % | $ 150 M | ||
|
BioMarin Pharmaceutical
BMRN
|
61 | $ 54.66 | 0.97 % | $ 10.5 B | ||
|
Benitec Biopharma
BNTC
|
13.5 | $ 11.25 | 2.46 % | $ 463 M | ||
|
Avenue Therapeutics
ATXI
|
0.42 | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
3.86 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
0.77 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
0.31 | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
0.5 | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
14.9 | $ 12.74 | - | $ 768 M | ||
|
Atreca
BCEL
|
1.27 | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
3.1 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
185 | - | 0.49 % | $ 251 B | ||
|
Coherus BioSciences
CHRS
|
1.93 | $ 1.59 | 4.28 % | $ 186 M | ||
|
Calithera Biosciences
CALA
|
13.3 | - | -10.95 % | $ 876 K | ||
|
Cellectis S.A.
CLLS
|
3.34 | $ 3.38 | 1.05 % | $ 116 M | ||
|
Cara Therapeutics
CARA
|
1 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
26.9 | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
8.23 | - | -74.18 % | $ 955 K | ||
|
Checkpoint Therapeutics
CKPT
|
4.04 | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
2.04 | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
12 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
19.3 | - | - | $ 867 M | ||
|
Compugen Ltd.
CGEN
|
2.1 | $ 2.13 | 1.9 % | $ 199 M | ||
|
Dyadic International
DYAI
|
1.67 | $ 0.86 | -8.51 % | $ 24.8 M | ||
|
Akero Therapeutics
AKRO
|
48.4 | - | - | $ 3.67 B | ||
|
CorMedix
CRMD
|
6.33 | $ 6.33 | 1.28 % | $ 456 K |